Literature DB >> 30930299

Phloretin inhibits Zika virus infection by interfering with cellular glucose utilisation.

Shih-Chao Lin1, Mei-Chun Chen2, Shufeng Liu2, Victoria M Callahan1, Nicole R Bracci1, Caitlin W Lehman1, Bibha Dahal1, Cynthia L de la Fuente1, Chi-Chen Lin3, Tony T Wang4, Kylene Kehn-Hall5.   

Abstract

Zika virus (ZIKV) is a re-emerging Flavivirus that has been linked to microcephaly and other neurological pathologies. In this study, phloretin, a glucose transporter inhibitor naturally derived from plants, was used to investigate the glucose dependence of ZIKV replication in host cells. The results showed that phloretin significantly decreased infectious titres of two ZIKV strains, namely MR766 (African genotype) and PRVABC59 (Puerto Rico genotype). The 50% effective concentration (EC50) of phloretin against MR766 and PRVABC59 was 22.85 µM and 9.31 µM, respectively. Further analyses demonstrated that decreased viral production was due to host-targeted inhibition, including decreased apoptotic caspase-3 and -7 activities and reduced phosphorylation of Akt/mTOR pathways. In addition, upon disruption of cellular glucose availability within host cells using 2-deoxy-d-glucose, ZIKV propagation was inhibited. Collectively, we demonstrate phloretin inhibition of ZIKV propagation and provide evidence of glucose utilization pathways as being important for ZIKV propagation. The activity of phloretin and its role in inhibiting glucose uptake could provide a useful foundation for the development of ZIKV antivirals.
Copyright © 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antiviral effect; Apoptosis; Flavonoid; Phloretin; Zika virus

Mesh:

Substances:

Year:  2019        PMID: 30930299     DOI: 10.1016/j.ijantimicag.2019.03.017

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

Review 1.  Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go.

Authors:  Juan-Carlos Saiz
Journal:  Pharmaceuticals (Basel)       Date:  2019-08-30

2.  Use of Nanotrap particles for the capture and enrichment of Zika, chikungunya and dengue viruses in urine.

Authors:  Shih-Chao Lin; Brian D Carey; Victoria Callahan; Ji-Hyun Lee; Nicole Bracci; Anurag Patnaik; Amy K Smith; Aarthi Narayanan; Benjamin Lepene; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

3.  Post-Vaccination Yellow Fever Antiserum Reduces Zika Virus in Embryoid Bodies When Placental Cells are Present.

Authors:  Emily M Schultz; TyAnthony J Jones; Hannah K Hopkins; Jingmei Zeng; Kelli L Barr
Journal:  Vaccines (Basel)       Date:  2020-12-11

4.  Receptor-Based Pharmacophore Modeling in the Search for Natural Products for COVID-19 Mpro.

Authors:  Mohd Saeed; Amir Saeed; Md Jahoor Alam; Mousa Alreshidi
Journal:  Molecules       Date:  2021-03-11       Impact factor: 4.411

Review 5.  Advancement in the Development of Therapeutics Against Zika Virus Infection.

Authors:  Kangchen Li; Qianting Ji; Shibo Jiang; Naru Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-07-08       Impact factor: 6.073

6.  In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2.

Authors:  Balaji Gowrivel Vijayakumar; Deepthi Ramesh; Annu Joji; Jayadharini Jayachandra Prakasan; Tharanikkarasu Kannan
Journal:  Eur J Pharmacol       Date:  2020-08-06       Impact factor: 4.432

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.